PT - JOURNAL ARTICLE AU - Alfano, Gaetano AU - Damiano, Francesca AU - Fontana, Francesco AU - Ferri, Camilla AU - Giaroni, Francesco AU - Melluso, Andrea AU - Montani, Martina AU - Morisi, Niccolò AU - Tei, Lorenzo AU - Plessi, Jessica AU - Giovanella, Silvia AU - Ligabue, Giulia AU - Mori, Giacomo AU - Guaraldi, Giovanni AU - Magistroni, Riccardo AU - Cappelli, Gianni TI - Effects of immunosuppressive therapy reduction and early post-infection graft function in kidney transplant recipients with COVID-19 AID - 10.1101/2021.06.06.21258414 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.06.21258414 4099 - http://medrxiv.org/content/early/2021/06/24/2021.06.06.21258414.short 4100 - http://medrxiv.org/content/early/2021/06/24/2021.06.06.21258414.full AB - Background Kidney transplant recipients with COVID-19 are at high risk of poor outcome because of comorbidities and immunosuppression. The effects of immunosuppressive therapy reduction are unclear in patients with COVID-19.Methods We conducted a retrospective study on 45 consecutive kidney transplant recipients followed at the University Hospital of Modena who tested positive for COVID-19 by RT-PCR analysis.Results The median age of patients was 56.1 (interquartile range, [IQR] 47.3-61.1) years with a predominance of male (64.4%). Kidney transplantation vintage was 10.1 (2.7-16) years, and more than half of patients (55.6%) was on triple immunosuppressive therapy. Early reduction of immunosuppression occurred in 62.8% of patients and included antimetabolite (88.8%) and calcineurin inhibitor withdrawal (22.2%).Of the 45 patients, 88.9% became symptomatic and 40% required hospitalization. Overall mortality was 17.8%. There were no differences in outcomes between full- and reduced-dose immunosuppressive therapy at the end of follow-up. One hospitalized patient experienced irreversible graft failure. There were no differences in serum creatinine level and proteinuria in non-hospitalized patients with COVID-19. Admitted patients had better kidney function after dismission (P=0.019). Risk factors for death were age (odds ratio [OR]: 1.19; 95%CI: 1.01-1.39), and duration of kidney transplant (OR: 1.17; 95%CI: 1.01-1.35). One kidney transplant recipient experienced symptomatic COVID-19 reinfection after primary infection and anti-SARS-CoV-2 mRNA vaccine.Conclusions Despite the reduction of immunosuppression, COVID-19 affected survival of kidney transplant recipients with COVID-19. Age and duration of kidney transplant were independent predictors of death in COVID-19. Early kidney function was favorable in most survivors after COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been authorized by the local Ethical Committee of Emilia Romagna IRB (n. 839/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to the corresponding author